In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GT Biopharma Inc.

https://www.gtbiopharma.com/

Latest From GT Biopharma Inc.

Pipeline Watch: Dismay With Veliparib, Tarextumab, House Dust Mite Allergens

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Tech Transfer Deals, October 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2015.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device

Oxis appoints new SAB member

Oxis International, a biotechnology company focused on cannabinoid therapy development and commercialization, has named Dr Lisa A Haile a member of the scientific advisory board for its wholly owned subsidiary, Oxis Biotech. Dr Haile currently serves as co-chair, global life sciences sector at DLA Piper, where she is also a member of the firm's executive committee. She has specific technical expertise in molecular biology and immunology.

Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Georgetown Translational Pharmaceuticals, Inc.
    • Oxis Biotech, Inc.
    • Oxis International, Inc.
UsernamePublicRestriction

Register